STOCK TITAN

Treace Medical Concepts (TMCI) CEO buys 115,520 shares of stock

(High)
(Positive)
Form Type
4

Rhea-AI Filing Summary

Treace Medical Concepts CEO John T. Treace increased his stake by buying 115,520 shares of common stock in open-market transactions. The purchases occurred on May 26, 27, and 28, 2026 at weighted average prices of about $2.79, $2.87, and $3.02 per share, respectively. After these direct purchases, he held 7,273,833 common shares, which include 542,784 restricted stock units. He also reports additional indirect holdings through trusts and his spouse, while expressly disclaiming beneficial ownership of those indirectly held shares.

Positive

  • None.

Negative

  • None.
Insider Treace John T.
Role Chief Executive Officer
Bought 115,520 shs ($341K)
Type Security Shares Price Value
Purchase Common Stock 61,202 $3.0199 $185K
Purchase Common Stock 49,810 $2.8747 $143K
Purchase Common Stock 4,508 $2.7897 $13K
holding Common Stock -- -- --
holding Common Stock -- -- --
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 7,273,833 shares (Direct); Common Stock — 1,605,000 shares (Indirect, By spouse)
Footnotes (1)
  1. The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $2.7600 to $2.8000 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. Includes 542,784 restricted stock units. The Reporting Person disclaims beneficial ownership of shares held by his wife directly or in trusts for which his wife serves as trustee or co-trustee. The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $2.7976 to $2.9400 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $2.8233 to $3.1150 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. The Reporting Person disclaims beneficial ownership of shares held in trust for which he serves as trustee or co-trustee.
Shares purchased May 26, 2026 4,508 shares at $2.7897 Open-market purchase of TMCI common stock
Shares purchased May 27, 2026 49,810 shares at $2.8747 Open-market purchase of TMCI common stock
Shares purchased May 28, 2026 61,202 shares at $3.0199 Open-market purchase of TMCI common stock
Total shares bought 115,520 shares Net open-market purchases over three days
Direct holdings after trades 7,273,833 shares TMCI common stock held directly by CEO after purchases
Restricted stock units included 542,784 RSUs RSUs included within direct share holdings
open-market purchase financial
"transaction_action: "open-market purchase""
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
restricted stock units financial
"Includes 542,784 restricted stock units."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
beneficial ownership financial
"The Reporting Person disclaims beneficial ownership of shares held by his wife"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
weighted average purchase price financial
"The price reported in Column 4 is a weighted average purchase price."
The weighted average purchase price is the average cost per share you paid across multiple buys, calculated so larger purchases count more than smaller ones. Imagine buying apples at different prices: the overall price you effectively paid depends on how many apples you bought at each price. Investors use it to measure true cost basis, calculate gains or losses, decide when to sell, and manage taxes and portfolio performance.
indirect ownership financial
"ownership_type: "indirect", nature_of_ownership: "As co-trustee of a trust""

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did TMCI CEO John T. Treace report?

John T. Treace reported open-market purchases of 115,520 TMCI common shares over three days. The Form 4 shows direct buying activity, indicating he added to his stake rather than selling shares during this period.

On which dates did TMCI’s CEO buy additional shares and at what prices?

He bought TMCI common stock on May 26, 27, and 28, 2026. Weighted average purchase prices were about $2.79, $2.87, and $3.02 per share, based on multiple trades within stated intraday price ranges.

How many TMCI shares does John T. Treace hold directly after these trades?

After the reported purchases, John T. Treace directly held 7,273,833 TMCI common shares. This amount includes 542,784 restricted stock units, which are share-based awards that typically vest over time according to company compensation plans.

How many TMCI shares did the CEO buy on each trading day?

He acquired 4,508 shares on May 26, 49,810 shares on May 27, and 61,202 shares on May 28, 2026. Altogether, these open-market purchases total 115,520 TMCI common shares over the three-day period.

Does the TMCI CEO have indirect holdings, and how are they treated?

The filing reports indirect holdings through trusts and his spouse. Footnotes state that John T. Treace disclaims beneficial ownership of shares held by his wife or in certain trusts where she or he serves as trustee or co-trustee.

What do the weighted average prices in the TMCI Form 4 mean?

Weighted average prices, such as $2.7897 or $3.0199, reflect multiple trades combined into one figure. Footnotes explain that shares were bought in several transactions within specified price ranges, and detailed breakdowns are available upon request.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Treace John T.

(Last)(First)(Middle)
C/O TREACE MEDICAL CONCEPTS, INC.
100 PALMETTO PARK PLACE

(Street)
PONTE VEDRA FLORIDA 32081

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
TREACE MEDICAL CONCEPTS, INC. [ TMCI ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirectorX10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/26/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/26/2026P4,508A$2.7897(1)7,162,821(2)D
Common Stock05/27/2026P49,810A$2.8747(4)7,212,631(2)D
Common Stock05/28/2026P61,202A$3.0199(5)7,273,833(2)D
Common Stock1,605,000(3)IBy spouse
Common Stock1,471,250(3)IBy spouse as trustee of a trust
Common Stock1,839,063(6)IAs trustee of a trust
Common Stock408,816(6)IAs co-trustee of a trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $2.7600 to $2.8000 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
2. Includes 542,784 restricted stock units.
3. The Reporting Person disclaims beneficial ownership of shares held by his wife directly or in trusts for which his wife serves as trustee or co-trustee.
4. The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $2.7976 to $2.9400 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
5. The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $2.8233 to $3.1150 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
6. The Reporting Person disclaims beneficial ownership of shares held in trust for which he serves as trustee or co-trustee.
/s/ Lisa Taylor as Attorney-in-fact for John Treace05/28/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)